

(18)



Europäisches Patentamt  
European Patent Office  
Office européen des brevets

(11) Publication number:

**0 346 957  
A1**

(12)

## EUROPEAN PATENT APPLICATION

(21) Application number: **89201204.8**

(61) Int. Cl.4: **A61K 7/16**

(22) Date of filing: **12.05.89**

(30) Priority: **19.05.88 GB 8811830**

(43) Date of publication of application:  
**20.12.89 Bulletin 89/51**

(84) Designated Contracting States:  
**CH DE ES FR GB IT LI NL SE**

(71) Applicant: **UNILEVER NV**  
**Burgemeester s'Jacobplein 1 P.O. Box 760**  
**NL-3000 DK Rotterdam(NL)**  
(84) **CH DE ES FR IT LI NL SE**

Applicant: **UNILEVER PLC**  
**Unilever House Blackfriars P.O. Box 68**  
**London EC4P 4BQ(GB)**  
(84) **GB**

(72) Inventor: **Bristow, Neil John**  
**71 Yarrum Avenue**  
**NSW 2322(AU)**  
Inventor: **Carter, Peter**  
**Briarfield The Rake Burton**  
**South Wirral Cheshire(GB)**  
Inventor: **Coulson, Bryony Emma**  
**7 Knox Close**  
**Port Sunlight Wirral(GB)**  
Inventor: **Trevethan, Michael Albert**  
**7 Warren Hey**  
**Bebington Wirral(GB)**

(74) Representative: **van Gent, Jan Paulus et al**  
**Unilever N.V. Patent Division P.O. Box 137**  
**NL-3130 AC Vlaardingen(NL)**

(54) Oral compositions.

EP 0 346 957 A1

(57) The present invention relates to oral compositions for treating sensitive teeth. These compositions comprise an agent for desensitising sensitive teeth, such as potassium nitrate or strontium acetate, and a particulate abrasive material which is hydroxyapatite. The hydroxyapatite is compatible with the desensitising agent.

## ORAL COMPOSITIONS

This invention relates to oral compositions and in particular to oral compositions containing an agent for desensitising sensitive teeth.

It is an object of the invention to provide an improved tooth desensitising composition.

The novel tooth desensitising oral composition of this invention comprises a combination of insoluble and soluble compounds each having a tooth desensitising action and wherein the insoluble compound also acts as a tooth cleaning and polishing agent.

Accordingly, the invention provides a tooth desensitising oral composition comprising a finely divided hydroxyapatite and a source of potassium and/or strontium ions.

It is already known to use finely divided hydroxyapatite as an abrasive of an oral composition (see CA-A-999 238, US-A-4 634 589 and US-A-4 327 079) but its use in products containing a source of potassium and/or strontium ions has not previously been suggested.

The hydroxyapatite abrasive is used in a particle size giving satisfactory cleaning without being harmful to the tooth surface when used in appropriate amounts in dentifrices of the invention. The average particle size will usually be in the range from about 1 micron to about 15 microns, preferably 2-10 and particularly preferably about 3 to about 10 microns.

Preferred particulate hydroxyapatites for use in oral compositions of this invention are synthetic hydroxyapatites of high purity consisting of at least 92% of  $\text{Ca}_{10}(\text{PO}_4)_6(\text{OH})_2$ . The remainder will comprise mainly bound water (typically 8% maximum) and a minor amount of calcium carbonate (typically 2% maximum). A process for the preparation of hydroxyapatites is described in GB-A-1 586 915 (British Charcoals & Macdonalds).

A highly pure synthetic hydroxyapatite available commercially is that sold under the trade name CAPITAL by British Charcoals & Macdonalds of Greenock, Scotland. This hydroxyapatite contains about 97%  $\text{Ca}_{10}(\text{PO}_4)_6(\text{OH})_2$ . The remaining 3% is mostly bound water with approximately 0.3% calcium carbonate.

The amount of the hydroxyapatite present in oral compositions of this invention will range from 1-50%, usually about 2% to about 20%, preferably 3 to 15%, by weight of the oral composition.

Various potassium and strontium compounds have been described in the literature for use as tooth desensitising agents. US-A-3 863 008 (Hodosh) describes the use of potassium nitrate. EP-A-95 871 (Reckitt and Colman) discloses the use of potassium citrate. PCT/US85/00123 (The Trustees of Columbia University in the City of New York) discloses the use of potassium bicarbonate and potassium chloride. A further effective potassium compound which is disclosed in our co-pending application 8708187 is potassium acetate.

US-A-3 122 483 (Block Drug Co.) discloses the use of water-soluble strontium compounds as tooth desensitising agents, such as strontium chloride, strontium lactate, strontium acetate, strontium bromide, strontium iodide, strontium nitrate and strontium salicylate. US-A-3 699 221 (Schole et al.) describes the use of a non-toxic, water-soluble ionic strontium compound selected from the class consisting of organic chelating agents and inorganic sequestering agents. Examples of such agents are strontium citrate, disodium salt of ethylenediamine tetraacetic acid, strontium gluconate and strontium gentisate.

The amount of the source of potassium or strontium ions will generally be from about 1% to about 20%, usually to about 10%, for example from 2% to 8%, more preferably 3-6% by weight of the oral composition.

An additional benefit which is already associated with the use of hydroxyapatite in the prior literature is a remineralising effect on tooth material.

Together with the hydroxyapatite and the source of potassium or strontium ions, the oral product of the invention will contain other conventional ingredients well known to those skilled in art depending on the form of the oral product. For instance, in the case of an oral product in the form of a dentifrice cream or paste, the product will comprise an humectant-containing liquid phase and a binder or thickener which acts to maintain the particulate solid abrasive in stable suspension in the liquid phase. A surfactant and a flavouring agent are also usual ingredients of commercially acceptable dentifrices.

Humectants commonly used are glycerol and sorbitol syrup (usually comprising an approximately 70% solution). However, other humectants are known to those in the art, including propylene glycol, lactitol and hydrogenated corn syrup. The amount of humectant will generally range from about 10 to 85% by weight of the dentifrice. The remainder of the liquid phase will consist substantially of water.

Likewise, numerous binding or thickening agents have been indicated for use in dentifrices, preferred ones being sodium carboxymethylcellulose and xanthan gum. Others include natural gum binders such as

Ingredient	%
Hydroxyapatite	5.00
Silica aerogel (Gasll 23)	10.00
Sorbitol syrup	40.00
Sodium lauryl sulphate	1.50
Sodium carboxymethylcellulose	1.00
Strontiu chloride	5.00
Sodium monofluorophosphate	0.78
Sodium saccharin	0.20
Titanium dioxide	1.00
Formalin	0.04
Flavour	1.00
Water	to 100.00

Examples 3 to 6

Toothpastes are made from the ingredlents indicated below.

Ingredient	% Example:			
	3	4	5	6
Hydroxyapatite	10.0	10.0	5.0	5.0
Thickening silica	10.0	10.0	10.0	10.0
Sorbitol syrup (708 solution)	40.0	40.0	40.0	40.0
Sodium lauryl sulphate	1.5	1.5	1.5	-
Sodium carboxymethylcellulose	1.0	1.0	1.0	1.0
Potassium nitrate	3.0	-	3.0	3.0
Strontium acetate	-	3.0	-	-
Sodium monofluorophosphate	0.8	0.8	0.8	0.8
Triclosan	0.2	-	-	-
Hexetidine	-	0.2	-	-
Polyethyleneglycol 300	6.0	-	-	-
Chlorhexidine digluconate	-	-	0.1	0.1
Stannous chloride	-	-	0.4	0.4
Sodium saccharin	1.2	0.2	0.2	0.2
Titanium dioxide	1.0	1.0	1.0	1.0
Formalin	0.04	0.04	0.04	0.04
Flavour	1.0	1.0	1.0	1.0
Water	all to 100.0	100.0	100.0	100.0

**Claims**

1. An oral composition for the treatment of sensitive teeth, comprising a source of potassium and/or strontium ions as desensitising agent, and a particulate abrasive material, characterized in that the particulate abrasive material is or comprises hydroxyapatite.

2. A preparation according to claim 1, characterised in that the hydroxyapatite has an average particle size of from 1 to 15 microns.

3. A preparation according to claim 1, characterised in that the hydroxyapatite is a synthetic hydroxyapatite which consists for at least 92% by weight of  $\text{Ca}_{10}(\text{PO}_4)_6(\text{OH})_2$ .

4. A preparation according to claim 1, characterised in that the hydroxyapatite is present in an amount of 1-50% by weight.

5. A composition according to claim 1, characterised in that the composition comprises from 1-10% by weight of the source of the potassium and/or strontium ions as desensitising agent.

5

10

15

20

25

30

35

40

45

50

55